11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles

Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles

Antimicrobial resistance (AMR) represents one of the most formidable threats to global public health and modern healthcare delivery. In Canadian hospitals and health authorities, Antimicrobial Stewardship Programs (ASPs) function as multidisciplinary systems designed to optimize clinical outcomes while minimizing collateral damage: drug-related toxicity, unnecessary costs, selective pressure for resistant pathogens, and secondary infections such as Clostridioides difficile.

---

Clostridioides difficile Infection (CDI): Pathogenesis & Clinical Staging

Clostridioides difficile is a spore-forming, toxin-producing, anaerobic Gram-positive bacillus transmitted via the fecal-oral route. Spores resist stomach acidity, germinate in the small bowel, and colonize the colon when the protective anaerobic intestinal microbiota is disrupted.

• Pathogenic Toxins: Pathogenic strains produce Toxin A (enterotoxin), which induces mucosal inflammation and intestinal hypersecretion, and Toxin B (cytotoxin), which is 10-fold more potent at disrupting epithelial tight junctions, triggering epithelial cell necrosis, mucosal pseudomembrane formation, and watery diarrhea.
• Antimicrobial Risk Hierarchy: Virtually all antibacterials can precipitate CDI, but the highest relative risks occur with fluoroquinolones, clindamycin, third- and fourth-generation cephalosporins, and carbapenems. Penicillins and macrolides carry intermediate risk, while aminoglycosides, tetracyclines, and vancomycin carry the lowest risk.
• Additional Host Risk Factors: Advanced age (≥ 65 years), prolonged hospitalization or ICU admission, immunosuppression, renal impairment, tube feeding, and concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists.

Clinical Severity Staging Criteria

Under Canadian and IDSA/SHEA clinical guidelines, CDI is categorized into three discrete severity tiers based on objective laboratory and hemodynamic markers:

---

CDI Pharmacotherapy: First-Line Regimens & Recurrence Strategies

                    [ Confirmed Toxigenic C. difficile Episode ]
                                         │
                         Assess Clinical Severity Tiers
                                         │
        ┌────────────────────────────────┼────────────────────────────────┐
        │                                │                                │
 [ Non-Severe CDI ]               [ Severe CDI ]                 [ Fulminant CDI ]
 (WBC <= 15 and SCr < 133)        (WBC > 15 or SCr >= 133)       (Shock, ileus, megacolon)
        │                                │                                │
 ┌──────┴──────┐                  ┌──────┴──────┐                 High-Dose Oral Vancomycin
 │ Preferred:  │                  │ Preferred:  │                 500 mg PO/NG QID
 │ Fidaxomicin │                  │ Fidaxomicin │                 PLUS IV Metronidazole
 │ 200 mg BID  │                  │ 200 mg BID  │                 500 mg IV Q8H
 │ x 10 days   │                  │ x 10 days   │                 (Add rectal vancomycin
 ├─────────────┤                  ├─────────────┤                  enema if ileus present)
 │ Alternative:│                  │ Alternative:│                 URGENT SURGICAL CONSULT
 │ Vancomycin  │                  │ Vancomycin  │
 │ 125 mg QID  │                  │ 125 mg QID  │
 │ x 10 days   │                  │ x 10 days   │
 └─────────────┘                  └─────────────┘

Initial Episode Pharmacotherapy

1. Preferred First-Line Agent: Oral Fidaxomicin
   • Dosage: 200 mg PO BID for 10 days.
   • Mechanism & Benefits: Fidaxomicin is a macrocyclic bactericidal agent that inhibits bacterial RNA polymerase. Because it has minimal systemic absorption and a narrow bactericidal spectrum, it preserves normal anaerobic colonic flora (Bacteroides spp.). Consequently, while clinical cure rates match vancomycin (~88%), fidaxomicin significantly reduces recurrence rates (~15% vs. ~25% with vancomycin).
2. Alternative First-Line Agent: Oral Vancomycin
   • Dosage: 125 mg PO QID for 10 days.
   • Clinical Efficacy: Highly effective at achieving initial symptom resolution. Oral capsules or reconstituted intravenous liquid administered orally achieve fecal concentrations exceeding 1,000 µg/g, far above the MIC.

Management of Fulminant CDI

• Pharmacotherapy: High-dose oral Vancomycin 500 mg PO (or via nasogastric tube) QID PLUS IV Metronidazole 500 mg IV Q8H.
• If Ileus is Present: Add Vancomycin retention enema (500 mg dissolved in 100 mL of 0.9% normal saline administered intrarectally Q6H) to ensure delivery of drug past the non-functioning colon.
• Surgical Consultation: Immediate surgical evaluation for subtotal colectomy or diverting loop ileostomy with colonic lavage.

Treatment of Recurrent CDI

Approximately 20% to 25% of patients experience a first recurrence, with risks rising to 40%–60% for subsequent recurrences:

• First Recurrence:
  • If vancomycin was used initially: Treat with Fidaxomicin 200 mg PO BID for 10 days (or extended-pulsed fidaxomicin: 200 mg BID on Days 1–5, then once every other day on Days 7–25).
  • If fidaxomicin was used initially: Use a tapered and pulsed oral vancomycin regimen (e.g., 125 mg QID for 10–14 days, then BID for 7 days, then daily for 7 days, then every 2 to 3 days for 2 to 8 weeks).
• Second or Subsequent Recurrences (Multiple Recurrent CDI):
  • Fecal Microbiota Transplantation (FMT): Administration of filtered human donor stool (via colonoscopy, enema, or encapsulated oral lyophilized product) restores complex anaerobic bowel microbiota and bile acid metabolism, achieving sustained cure rates exceeding 85%–90%.
  • Bezlotoxumab (historical): This anti-toxin B monoclonal antibody was given as a single IV infusion to reduce recurrence in high-risk patients. The manufacturer discontinued it worldwide in January 2025, so it is no longer an option. Older references and question banks may still list it.

---

Antimicrobial Stewardship Programs (ASP): Core & Supplemental Strategies

Antimicrobial Stewardship Programs promote the optimal selection, posology, route, and duration of antimicrobial therapy to optimize clinical cures while minimizing unintended adverse consequences.

The Two Core Active Strategies

1. Prospective Audit with Intervention and Feedback (PAF):
   • An infectious disease pharmacist or specialist reviews antimicrobial orders in real-time (typically at 48 to 72 hours post-admission, coinciding with microbiology culture and susceptibility reporting).
   • The pharmacist communicates actionable clinical recommendations directly to the treating prescriber (e.g., de-escalation, dose adjustment, duration optimization, or discontinuation).
   • Advantage: Prescriber autonomy is preserved, fostering direct interprofessional education with high recommendation acceptance rates (> 80%).
2. Formulary Restriction and Pre-Authorization:
   • Specific broad-spectrum or high-cost agents (e.g., carbapenems, daptomycin, linezolid, ceftolozane-tazobactam) require formal clinical review and approval from the ASP team before the hospital pharmacy dispenses the drug.
   • Advantage: Immediately curbs unwarranted broad-spectrum use, prevents inappropriate empiric broad-spectrum prescribing, and produces immediate drug expenditure savings.

Supplemental Antimicrobial Stewardship Strategies

• IV-to-Oral Step-Down (Switch) Programs: Criteria for converting patients from parenteral to oral therapy include: intact functioning gastrointestinal tract (tolerating oral diet and medications), hemodynamic stability, afebrile for ≥ 24 hours with normalizing inflammatory markers, and availability of an oral antimicrobial with high bioavailability (> 85%–90%), such as fluoroquinolones, linezolid, metronidazole, fluconazole, clindamycin, doxycycline, or TMP-SMX.
• Antibiotic De-escalation (Streamlining): Narrowing the antimicrobial spectrum once microbiological identification and susceptibility testing are finalized (e.g., discontinuing empiric vancomycin and transitioning to cefazolin or cloxacillin upon confirmation of MSSA bacteremia).
• Diagnostic Stewardship: Integrating rapid multiplex polymerase chain reaction (PCR) blood culture identification panels (BCID) and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) to identify pathogens and resistance genes (e.g., mecA, vanA) within hours of blood culture positivity, reducing time to optimal targeted therapy by 24 to 48 hours.

---

Pharmacokinetic / Pharmacodynamic (PK/PD) Optimization

Optimizing antimicrobial efficacy requires tailoring dosing regimens to the specific pharmacodynamic index that drives bacterial eradication:

┌─────────────────────────────────────────────────────────────────────────────────┐
│                            PK/PD PATTERNS & TARGETS                             │
├──────────────────────────┬──────────────────────────┬───────────────────────────┤
│  Time-Dependent Killing  │ Concentration-Dependent  │    Exposure-Dependent     │
│        (T > MIC)         │       (Cmax / MIC)       │       (AUC / MIC)         │
├──────────────────────────┼──────────────────────────┼───────────────────────────┤
│ • Beta-lactams           │ • Aminoglycosides        │ • Vancomycin              │
│   (Penicillins,          │   (Gentamicin,           │ • Fluoroquinolones        │
│    Cephalosporins,       │    Tobramycin, Amikacin) │ • Daptomycin              │
│    Carbapenems)          │                          │                           │
│ • Goal: %fT > MIC        │ • Goal: Cmax/MIC >= 8-10 │ • Goal: AUC24/MIC         │
│   for 40%-70% of interval│ • Strategy: High-dose,   │   = 400-600 (Vancomycin)  │
│ • Strategy: Extended or  │   extended-interval      │ • Strategy: Area-under-   │
│   continuous infusions   │   once-daily dosing      │   the-curve monitoring    │
└──────────────────────────┴──────────────────────────┴───────────────────────────┘

1. Time-Dependent Killing (T > MIC): Beta-Lactams

• Agents: Penicillins, cephalosporins, carbapenems, monobactams.
• Core Index: The percentage of the dosing interval that free (unbound) drug concentration remains above the pathogen's minimum inhibitory concentration (%fT > MIC). Maximal bactericidal killing occurs at 40%–50% for penicillins, 50%–60% for cephalosporins, and 40% for carbapenems.
• Stewardship Dosing Optimization: Higher peak concentrations do not enhance killing. Rather, prolonging infusion duration maintains serum levels above the MIC for a greater fraction of time. Administering piperacillin-tazobactam as an extended infusion (3.375–4.5 g infused over 4 hours every 8 hours) or meropenem (1–2 g over 3 hours) improves clinical cure rates and lowers mortality in critically ill patients with severe sepsis or elevated MIC organisms.

2. Concentration-Dependent Killing (Cmax / MIC): Aminoglycosides

• Agents: Gentamicin, tobramycin, amikacin.
• Core Index: Ratio of peak drug concentration to the minimum inhibitory concentration (Cmax / MIC), with a target of 8 to 10:1.
• Stewardship Dosing Optimization: High-Dose Extended-Interval (Once-Daily) Dosing (5 to 7 mg/kg IV once every 24 hours). Maximizes the peak concentration to optimize rapid bactericidal killing and the post-antibiotic effect (PAE) (suppression of bacterial regrowth for hours after concentrations fall below the MIC). Furthermore, allowing a prolonged drug-free interval allows intracellular aminoglycoside to wash out of the renal proximal tubule cells and inner ear perilymph, substantially reducing nephrotoxicity and ototoxicity compared to traditional multiple daily dosing (e.g., 1.5 mg/kg Q8H).

3. Exposure-Dependent Killing (AUC24 / MIC): Vancomycin

• Agents: Vancomycin, fluoroquinolones, daptomycin.
• Core Index: The ratio of the 24-hour area under the concentration-time curve to the MIC (AUC24 / MIC). For vancomycin treating serious MRSA infections, the target is 400 to 600 mg·h/L (assuming broth microdilution MIC ≤ 1 mg/L).
• Clinical Practice Update: Trough-only monitoring (15–20 mg/L) has been superseded by Bayesian-guided or two-point pharmacokinetic AUC monitoring (drawing a peak and trough). AUC-guided dosing achieves target therapeutic exposure while cutting vancomycin-induced acute kidney injury (AKI) rates in half.

---

Antibiograms & Duration Optimization ("Shorter is Better")

Cumulative Antibiogram Interpretation

Hospital and regional antibiograms synthesize local microbiological susceptibility profiles over a 12-month period to guide empiric prescribing:

• CLSI Reliability Rule: The Clinical and Laboratory Standards Institute (CLSI) mandates a minimum threshold of at least 30 isolates per bacterial species to publish a statistically valid susceptibility percentage. Antibiogram entries with < 30 isolates carry excessive sample bias and must be interpreted with extreme caution.
• De-duplication: Only the first diagnostic isolate per patient per surveillance window should be counted, preventing chronically colonized intensive-care patients from skewing community-wide resistance estimates.

Duration Optimization: "Shorter is Better"

Excessive antibiotic duration fuels selective pressure without improving clinical outcomes. Robust randomized trials prove that shorter durations achieve equivalent clinical and microbiological cure:

---

Penicillin Allergy De-Labeling & Cephalosporin Cross-Reactivity

Approximately 10% of the Canadian population carries a documented penicillin allergy in their medical record. However, greater than 90% to 95% of these patients are NOT truly allergic upon formal skin testing or oral amoxicillin challenge. Over-reporting stems from remote non-allergic childhood viral exanthems, common drug side effects (nausea, mild diarrhea), or natural waning of IgE antibodies over 10 or more years.

The Heavy Clinical Toll of False Allergy Labels

Unwarranted penicillin allergy labels force clinicians to prescribe broad-spectrum second-line agents (vancomycin, fluoroquinolones, clindamycin, carbapenems), directly causing:

• 3-fold higher rates of Clostridioides difficile infection;
• Increased risk of MRSA and vancomycin-resistant enterococci (VRE);
• Significantly increased rates of surgical site infections (due to inferior alternative perioperative prophylaxis);
• Prolonged hospital stays and higher readmission rates.

Structural Science of Cephalosporin Cross-Reactivity

The historic teaching that all beta-lactams carry a 10% cross-reactivity rate is an obsolete clinical myth based on 1960s/1970s studies evaluating early cephalosporin batches contaminated with residual benzylpenicillin. True cross-reactivity between penicillins and modern cephalosporins is less than 1% to 2%.

                      [ Cephalosporin Chemical Backbone ]
                                     
                     R1 ── [ 7-aminocephalosporanic acid ] ── R2
                                 (Beta-Lactam Ring)

  * FACT: Allergic cross-reactivity is driven by R1 SIDE-CHAIN HOMOLOGY, 
          NOT by the shared core beta-lactam ring!

  * Aminopenicillin side chains (Amoxicillin, Ampicillin) share R1 homology with:
    - Cephalexin, Cefadroxil, Cefprozil (Cross-reactivity potential ~2%-5%)

  * Third- and Fourth-Generation Cephalosporins (Ceftriaxone, Cefotaxime, Cefepime)
    possess distinct methoxyimino R1 side chains (Cross-reactivity < 1%)

  * Cefazolin has a UNIQUE R1 side chain that shares NO homology with any 
    penicillin or cephalosporin (Cross-reactivity ~0%)

Safe Prescribing Rules in Penicillin Allergy

1. Mild Non-IgE Reactions (Delayed maculopapular rash without blisters or systemic symptoms): Patients can safely receive any third- or fourth-generation cephalosporin (e.g., ceftriaxone, cefotaxime, cefepime), cefazolin, or carbapenems without skin testing.
2. Severe IgE-Mediated Reactions (Anaphylaxis, angioedema, bronchospasm, urticaria within 1 hour):
   • Avoid cephalosporins that share identical or similar R1 side chains (e.g., avoid cephalexin or cefprozil in ampicillin/amoxicillin allergy).
   • Cefazolin can be safely administered even in history of penicillin anaphylaxis because its R1 side chain is chemically distinct from all penicillins.
   • Carbapenems (e.g., meropenem) demonstrate < 1% cross-reactivity and may be administered under clinical observation.
   • Aztreonam (a monobactam) shares no cross-reactivity with penicillins and can be safely administered to penicillin-allergic patients (except in confirmed ceftazidime allergy, with which aztreonam shares an identical R1 side chain).
3. Severe Non-IgE Reactions (SJS, TEN, DRESS, acute interstitial nephritis): An absolute contraindication to ALL beta-lactam antibiotics. Desensitization is strictly prohibited.

---

Clinical Case Vignette: Severe CDI & Post-Antibiotic Stewardship Review

A 74-year-old female admitted for a severe diabetic foot ulcer was treated with IV piperacillin-tazobactam and IV vancomycin for 12 days. On hospital day 13, she develops acute watery diarrhea (8 unformed stools in 24 hours), diffuse lower abdominal cramping, and low-grade fever. Laboratory analysis reveals: WBC count 19.4 × 10^9/L, Serum Creatinine 164 µmol/L (baseline 78 µmol/L), Blood Pressure 124/76 mmHg, Heart Rate 88 bpm. Stool nucleic acid amplification testing (NAAT) and enzyme immunoassay (EIA) confirm toxigenic Clostridioides difficile.

Pharmacist Clinical Assessment & Intervention:

1. Staging CDI Severity: The patient's WBC count is > 15.0 × 10^9/L (19.4 × 10^9/L) and serum creatinine is ≥ 133 µmol/L (164 µmol/L, which is also > 2× baseline). She meets the definition for Severe Clostridioides difficile Infection (non-fulminant, as she is hemodynamically stable without shock, ileus, or megacolon).
2. Antimicrobial Selection: Under updated clinical practice guidelines, the preferred first-line agent is Oral Fidaxomicin 200 mg PO BID for 10 days (or oral Vancomycin 125 mg PO QID for 10 days as an established alternative). Oral metronidazole is completely inappropriate due to treatment inferiority in severe disease.
3. Stewardship Action: Immediately discontinue the inciting antimicrobial agents (piperacillin-tazobactam and vancomycin), as the diabetic ulcer has achieved adequate surgical debridement and source control. Discontinuing inciting antibiotics substantially reduces the risk of CDI relapse.
4. Supportive Care & Deprescribing: Discontinue her concurrent proton pump inhibitor (pantoprazole 40 mg daily), which has no current active gastrointestinal bleeding indication, and avoid all antimotility agents (e.g., loperamide) to prevent precipitating toxic megacolon.